Toronto Stock Exchange Symbol: CYT
MONTREAL, April 3 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), the
global leader in cryotherapy products to treat cardiac arrhythmias, today
announced that data on the Company's Arctic Front(R) catheter system to
treat Atrial Fibrillation (AFib) was presented at the 74th Annual Meeting
of the German Cardiac Society in Mannheim, Germany, March 27-29, 2008.
CryoCath was well represented at the meeting, with a record number of
presentations on cryo-ablation. In total there were eight poster
presentations and ten oral presentations, including a standing room only
cryo symposium from leading electrophysiologists that received 50 percent
more attendance than the previous year.
Some of the highlights of the meeting include:
- Data from a three centre AFib study on Arctic Front by Professor Dr.
Schumacher from Herz- und GefaB-Klinik in Bad Neustadt, Germany,
Dr. Pitschner from the Kerckhoff-Klinik in Bad Nauheim, Germany and
Dr. Vogt from the Herz und Diabetes Zentrum NRW in Bad Oeynhausen,
Germany. With a median follow-up time of 12 months, 74 percent of the
293 paroxysmal patients enrolled were AFib free after only one
procedure and off anti-arrhythmic drugs (AADs).
- Dr. Heintze, also from the Herz und Diabetes Zentrum NRW, presented
follow up data on 168 patients treated in his center. This data
includes patients from the three center AFib study listed above as
well as a significant number of patients treated subsequently. The
group of AFib sufferers was largely paroxysmal with approximately
7 percent persistent. After an average of 8.5 months follow up,
81 percent were AFib free and off drugs and more than 85 percent were
considered a cli
|SOURCE CryoCath Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved